REVIEW MODIFIKASI KELARUTAN PIROKSIKAM
Abstract
Kata kunci: kokristal, dispersi padat, piroksikam, kelarutan, disolusi
Full Text:
Download (PDF) (Bahasa Indonesia)References
Shohin IE, Kulinich JI, Ramenskaya G V., Abrahamsson B, Kopp S, Langguth P, et al. Biowaiver monographs for immediate release solid oral dosage forms: Piroxicam. J Pharm Sci. 2014;103(2):367–77.
Banchero M, Manna L. Investigation of the piroxicam/hydroxypropyl-β-cyclodextrin inclusion complexation by means of a supercritical solvent in the presence of auxiliary agents. J Supercrit Fluids [Internet]. 2011;57(3):259–66. Available from: http://dx.doi.org/10.1016/j.supflu.2011.04.006
Gwak HS, Choi JS, Choi HK. Enhanced bioavailability of piroxicam via salt formation with ethanolamines. Int J Pharm. 2005;297(1–2):156–61.
Paaver U, Lust A, Mirza S, Rantanen J, Veski P, Heinämäki J, et al. Insight into the solubility and dissolution behavior of piroxicam anhydrate and monohydrate forms. Int J Pharm [Internet]. 2012;431(1–2):111–9. Available from: http://dx.doi.org/10.1016/j.ijpharm.2012.04.042
VreÄer F, Vrbinc M, Meden A. Characterization of piroxicam crystal modifications. Int J Pharm. 2003;256(1–2):3–15.
Nyström M, Roine J, Murtomaa M, Mohan Sankaran R, Santos HA, Salonen J. Solid state transformations in consequence of electrospraying - A novel polymorphic form of piroxicam. Eur J Pharm Biopharm. 2015;89(December):182–9.
Rasetti-Escargueil C, Grangé V. Pharmacokinetic profiles of two tablet formulations of piroxicam. Int J Pharm. 2005;295(1–2):129–34.
Kavanagh ON, Croker DM, Walker GM, Zaworotko MJ. Pharmaceutical cocrystals: from serendipity to design to application. Drug Discov Today [Internet]. 2018; Available from: https://linkinghub.elsevier.com/retrieve/pii/S1359644618303751
Sridhar I, Doshi A, Joshi B, Wankhede V, Doshi J. Solid Dispersions: an Approach to Enhance Solubility of poorly Water Soluble Drug. J Sci Innov Res. 2013;2(3):685–94.
Quirk RA, France RM, Shakesheff KM, Howdle SM. Supercritical fluid technologies and tissue engineering scaffolds. Curr Opin Solid State Mater Sci. 2004;8(3–4):313–21.
El-Badry M, Fathy M. Properties of solid dispersion of piroxicam in Pluronic F-98. J Drug Deliv Sci Technol. 2004;14(3):199–205.
Cerreia Vioglio P, Chierotti MR, Gobetto R. Pharmaceutical aspects of salt and cocrystal forms of APIs and characterization challenges. Adv Drug Deliv Rev [Internet]. 2017;117:86–110. Available from: https://doi.org/10.1016/j.addr.2017.07.001
Douroumis D, Ross SA, Nokhodchi A. Advanced methodologies for cocrystal synthesis. Adv Drug Deliv Rev [Internet]. 2017;117:178–95. Available from: http://dx.doi.org/10.1016/j.addr.2017.07.008
Arunan E, Desiraju GR, Klein RA, Sadlej J, Scheiner S, Alkorta I, et al. Definition of the hydrogen bond (IUPAC Recommendations 2011). Pure Appl Chem. 2011;83(8):1637–41.
Bavishi DD, Borkhataria CH. Spring and parachute: How cocrystals enhance solubility. Prog Cryst Growth Charact Mater [Internet]. 2016;62(3):1–8. Available from: http://dx.doi.org/10.1016/j.pcrysgrow.2016.07.001
Mirza S, Miroshnyk I, Habib MJ, Brausch JF, Hussain MD. Enhanced dissolution and oral bioavailability of piroxicam formulations: Modulating effect of phospholipids. Pharmaceutics. 2010;2(4):339–50.
Manin AN, Voronin AP, Drozd K V, Manin NG, Bauer-Brandl A, Perlovich GL. Cocrystal screening of hydroxybenzamides with benzoic acid derivatives: a comparative study of thermal and solution-based methods. Eur J Pharm Sci. 2014;65:56–64.
Fucke K, Myz SA, Shakhtshneider TP, Boldyreva E V., Griesser UJ. How good are the crystallisation methods for co-crystals? A comparative study of piroxicam. New J Chem. 2012;36(10):1969–77.
Aakeröy CB, Rajbanshi A, Li ZJ, Desper J. Mapping out the synthetic landscape for re-crystallization, co-crystallization and salt formation. CrystEngComm. 2010;12(12):4231–9.
Okabe N, Suga T. 3-(p-Hydroxyphenyl) propionic Acid. Acta Crystallogr Sect C Cryst Struct Commun. 1995;51(7):1324–5.
Rodrigues M, Baptista B, Loper JA, Sarraguca MC. Pharmaceutical cocrystallization techniques. Advances and challenges. Int J Pharm. 2018;574:404–20.
Iveson SM, Litster JD, Hapgood K, Ennis BJ. Nucleation, growth and breakage phenomena in agitated wet granulation processes: a review. Powder Technol. 2001;117(1–2):3–39.
Vehring R, Foss WR, Lechuga-Ballesteros D. Particle formation in spray drying. J Aerosol Sci. 2007;38(7):728–46.
Grossjohann C, Serrano DR, Paluch KJ, O’Connell P, Vella-Zarb L, Manesiotis P, et al. Polymorphism in sulfadimidine/4-aminosalicylic acid cocrystals: solid-state characterization and physicochemical properties. J Pharm Sci. 2015;104(4):1385–98.
Patil SP, Modi SR, Bansal AK. Generation of 1: 1 carbamazepine: nicotinamide cocrystals by spray drying. Eur J Pharm Sci. 2014;62:251–7.
Wang I-C, Lee M-J, Sim S-J, Kim W-S, Chun N-H, Choi GJ. Anti-solvent co-crystallization of carbamazepine and saccharin. Int J Pharm. 2013;450(1–2):311–22.
Lange L, Heisel S, Sadowski G. Predicting the solubility of pharmaceutical cocrystals in solvent/anti-solvent mixtures. Molecules. 2016;21(5):593.
Padrela L, Rodrigues MA, Velaga SP, Matos HA, de Azevedo EG. Formation of indomethacin–saccharin cocrystals using supercritical fluid technology. Eur J Pharm Sci. 2009;38(1):9–17.
Eddleston MD, Patel B, Day GM, Jones W. Cocrystallization by freeze-drying: preparation of novel multicomponent crystal forms. Cryst Growth Des. 2013;13(10):4599–606.
Emami S, Adibkia K, Barzegar-Jalali M, Siahi-Shadbad M. Piroxicam cocrystals with phenolic coformers: preparation, characterization, and dissolution properties. Pharm Dev Technol [Internet]. 2018;0(0):1–12. Available from: http://dx.doi.org/10.1080/10837450.2018.1455210
Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. Cryst growth Des. 2009;9(6):2950–67.
DOI: http://dx.doi.org/10.52434/jfb.v11i1.697
Refbacks
- There are currently no refbacks.
Visitor :